Journal of Gastrointestinal Cancer

, Volume 50, Issue 1, pp 78–83 | Cite as

Disregulation of miR-216a and miR-217 in Gastric Cancer and Their Clinical Significance

  • Reza Safaralizadeh
  • Naser Ajami
  • Masoumeh NematiEmail author
  • Mohammadali Hosseinpourfeizi
  • Arash Azimzadeh Isfanjani
  • Seyed-Yaghob Moaddab
Original Research



The majority of gastric cancer (GC) diagnoses occur at the middle or late stage of the disease, indicating that finding novel biomarkers that could be detectable at earlier stage is urgently needed. Accumulating studies have shown that microRNAs, a class of tiny single-stranded RNAs, play important roles in multiple biological processes including cancer development. The present study aimed to evaluate the effect of miR-216a and miR-217 in GC.

Material and Methods

The real-time quantitative reverse-transcription PCR was exploited to identify and compare the expression levels of miR-216a and miR-217 in 37 pairs of samples of gastric cancer tissue and adjacent normal tissue. Superimposed on this, the potential relationship between miR-216a/217 levels and clinicopathological parameters in patients suffering GC was explored.


The results obtained from this study showed that the miR-216a is significantly upregulated in gastric cancer tissues, compared with adjacent normal tissues, but the altered expression of miR-217 was not significant. For miR-216a/217, no significant correlations were detected between expression levels of these miRNAs and clinical and pathological characteristics of patients.


This prospective study proposes that upregulation of miR-216a might represent an important mechanism for the development of gastric cancer.


miR-216a miR-217 Gastric cancer Expression analysis qPCR 



We express our gratitude to the patients and the staff within the Endoscopy Department of Tabriz Emam Reza and Sina Hospitals and the faculty and staff at Department of Biology of the Tabriz University for their helpful collaborations.

Funding Information

This work was supported by grants from the Department of Biology, Faculty of Natural Sciences, Tabriz University.

Compliance with Ethical Standards

Conflict of Interest

The authors declare no conflict of interest.


  1. 1.
    Wadhwa R, Song S, Lee J-S, Yao Y, Wei Q, Ajani JA. Gastric cancer—molecular and clinical dimensions. Nat Rev Clin Oncol. 2013;10(11):643–55. Scholar
  2. 2.
    Malekzadeh R, Derakhshan MH, Malekzadeh Z. Gastric cancer in Iran: epidemiology and risk factors. Arch Iran Med. 2009;12(6):576–83.PubMedGoogle Scholar
  3. 3.
    Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014;64(1):9–29. Scholar
  4. 4.
    Karimi P, Islami F, Anandasabapathy S, Freedman ND, Kamangar F. Gastric cancer: descriptive epidemiology, risk factors, screening, and prevention. Cancer Epidemiol Biomark Prev. 2014;23(5):700–13. Scholar
  5. 5.
    Morris KV, Mattick JS. The rise of regulatory RNA. Nat Rev Genet. 2014;15(6):423–37. Scholar
  6. 6.
    Ling H, Fabbri M, Calin GA. MicroRNAs and other non-coding RNAs as targets for anticancer drug development. Nat Rev Drug Discov. 2013;12(11):847–65. Scholar
  7. 7.
    He L, Hannon GJ. MicroRNAs: small RNAs with a big role in gene regulation. Nat Rev Genet. 2004;5(7):522–31. Scholar
  8. 8.
    Shomron N. MicroRNAs and developmental robustness: a new layer is revealed. PLoS Biol. 2010;8(6):e1000397. Scholar
  9. 9.
    Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;116(2):281–97.CrossRefPubMedGoogle Scholar
  10. 10.
    Felekkis K, Touvana E, Stefanou C, Deltas C. microRNAs: a newly described class of encoded molecules that play a role in health and disease. Hippokratia. 2010;14(4):236–40.PubMedPubMedCentralGoogle Scholar
  11. 11.
    Wong N, Wang X. miRDB: an online resource for microRNA target prediction and functional annotations. Nucleic Acids Res. 2014:doi.
  12. 12.
    Li PF, Chen SC, Xia T, Jiang XM, Shao YF, Xiao BX, et al. Non-coding RNAs and gastric cancer. World J Gastroenterol: WJG. 2014;20(18):5411–9. Scholar
  13. 13.
    Beckman JD, Chen C, Nguyen J, Thayanithy V, Subramanian S, Steer CJ, et al. Regulation of heme oxygenase-1 protein expression by miR-377 in combination with miR-217. J Biol Chem. 2011;286(5):3194–202. Scholar
  14. 14.
    Hu B, El Hajj N, Sittler S, Lammert N, Barnes R, Meloni-Ehrig A. Gastric cancer: classification, histology and application of molecular pathology. J Gastrointest Oncol. 2012;3(3):251–61. Scholar
  15. 15.
    Almhanna K, Strosberg J, Malafa M. Targeting AKT protein kinase in gastric cancer. Anticancer Res. 2011;31(12):4387–92.PubMedGoogle Scholar
  16. 16.
    Dicken BJ, Bigam DL, Cass C, Mackey JR, Joy AA, Hamilton SM. Gastric adenocarcinoma: review and considerations for future directions. Ann Surg. 2005;241(1):27–39.PubMedPubMedCentralGoogle Scholar
  17. 17.
    Qi P, Du X. The long non-coding RNAs, a new cancer diagnostic and therapeutic gold mine. Mod Pathol. 2013;26(2):155–65.CrossRefPubMedGoogle Scholar
  18. 18.
    Benes V, Castoldi M. Expression profiling of microRNA using real-time quantitative PCR, how to use it and what is available. Methods. 2010;50(4):244–9. Scholar
  19. 19.
    Yin Y, Li J, Chen S, Zhou T, Si J. MicroRNAs as diagnostic biomarkers in gastric cancer. Int J Mol Sci. 2012;13(10):12544–55. Scholar
  20. 20.
    Volkomorov V, Grigoryeva E, Krasnov G, Litviakov N, Tsyganov M, Karbyshev M, et al. Search for potential gastric cancer markers using miRNA databases and gene expression analysis. Exp Oncol. 2013;35(1):2–7.PubMedGoogle Scholar
  21. 21.
    Yokota T, Ishiyama S, Saito T, Teshima S, Narushima Y, Murata K, et al. Lymph node metastasis as a significant prognostic factor in gastric cancer: a multiple logistic regression analysis. Scand J Gastroenterol. 2004;39(4):380–4.CrossRefPubMedGoogle Scholar
  22. 22.
    Ding X-M. MicroRNAs: regulators of cancer metastasis and epithelial-mesenchymal transition (EMT). Chin J Cancer. 2014;33(3):140–7. Scholar
  23. 23.
    Mareel M, Leroy A. Clinical, cellular, and molecular aspects of cancer invasion. Physiol Rev. 2003;83(2):337–76. Scholar
  24. 24.
    Fu H, Hu Z, Wen J, Wang K, Liu Y. TGF-beta promotes invasion and metastasis of gastric cancer cells by increasing fascin1 expression via ERK and JNK signal pathways. Acta Biochim Biophys Sin. 2009;41(8):648–56.CrossRefPubMedGoogle Scholar
  25. 25.
    Xia H, Ooi LLPJ, Hui KM. MicroRNA-216a/217-induced epithelial-mesenchymal transition targets PTEN and SMAD7 to promote drug resistance and recurrence of liver cancer. Hepatology. 2013;58(2):629–41. Scholar
  26. 26.
    Inui M, Martello G, Piccolo S. MicroRNA control of signal transduction. Nat Rev Mol Cell Biol. 2010;11(4):252–63.
  27. 27.
    Matsuoka T, Yashiro M. The role of PI3K/Akt/mTOR signaling in gastric carcinoma. Cancers. 2014;6(3):1441–63. Scholar
  28. 28.
    Piguet A-C, Dufour J-F. PI(3)K/PTEN/AKT pathway. Journal of Hepatology. 54(6):1317–9.
  29. 29.
    Kato M, Putta S, Wang M, Yuan H, Lanting L, Nair I, et al. TGF-beta activates Akt kinase through a microRNA-dependent amplifying circuit targeting PTEN. Nat Cell Biol. 2009;11(7):881–9.CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Liu H-S, Xiao H-S. MicroRNAs as potential biomarkers for gastric cancer. World J Gastroenterol: WJG. 2014;20(34):12007–17. Scholar

Copyright information

© Springer Science+Business Media, LLC 2017

Authors and Affiliations

  • Reza Safaralizadeh
    • 1
  • Naser Ajami
    • 2
  • Masoumeh Nemati
    • 1
    Email author
  • Mohammadali Hosseinpourfeizi
    • 1
  • Arash Azimzadeh Isfanjani
    • 1
  • Seyed-Yaghob Moaddab
    • 3
  1. 1.Department of Biology, Faculty of Natural SciencesUniversity of TabrizTabrizIran
  2. 2.Department of Medical Genetics, School of MedicineMashhad University of Medical SciencesMashhadIran
  3. 3.Liver and Gastroenterology Diseases Research CenterTabriz University of Medical SciencesTabrizIran

Personalised recommendations